Insulet (NASDAQ:PODD) Price Target Lowered to $208.00 at Bank of America

Insulet (NASDAQ:PODD) had its price target reduced by investment analysts at Bank of America from $288.00 to $208.00 in a report issued on Monday,Benzinga reports. The brokerage presently has a “buy” rating on the medical instruments supplier’s stock. Bank of America‘s target price suggests a potential upside of 36.36% from the stock’s previous close.

Several other research analysts have also recently weighed in on the stock. Barclays cut their price target on shares of Insulet from $286.00 to $198.00 and set an “underweight” rating on the stock in a report on Thursday, May 7th. The Goldman Sachs Group set a $237.00 price target on shares of Insulet in a research note on Thursday, May 7th. Oppenheimer dropped their price objective on Insulet from $300.00 to $210.00 and set an “outperform” rating on the stock in a report on Thursday, May 7th. Sanford C. Bernstein dropped their price target on Insulet from $330.00 to $200.00 and set an “outperform” rating for the company in a research report on Thursday, May 7th. Finally, JPMorgan Chase & Co. dropped their price objective on shares of Insulet from $340.00 to $275.00 and set an “overweight” rating for the company in a report on Thursday, May 7th. Twenty analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $254.96.

Insulet Trading Up 3.4%

NASDAQ PODD traded up $5.08 during mid-day trading on Monday, reaching $152.54. 773,593 shares of the stock were exchanged, compared to its average volume of 1,131,386. The stock has a 50 day simple moving average of $199.93 and a 200-day simple moving average of $256.50. Insulet has a one year low of $145.59 and a one year high of $354.88. The stock has a market cap of $10.57 billion, a P/E ratio of 35.58, a P/E/G ratio of 1.20 and a beta of 1.20. The company has a debt-to-equity ratio of 0.71, a current ratio of 2.49 and a quick ratio of 1.81.

Insulet (NASDAQ:PODD) last posted its quarterly earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 EPS for the quarter, topping analysts’ consensus estimates of $1.19 by $0.23. The business had revenue of $761.70 million during the quarter, compared to analysts’ expectations of $729.89 million. Insulet had a net margin of 10.44% and a return on equity of 26.87%. The business’s quarterly revenue was up 33.9% on a year-over-year basis. During the same period last year, the company posted $1.02 earnings per share. Insulet has set its FY 2026 guidance at 6.210- EPS. On average, analysts anticipate that Insulet will post 6.44 EPS for the current year.

Insider Buying and Selling

In other Insulet news, Director Michael R. Minogue purchased 2,030 shares of the stock in a transaction that occurred on Wednesday, February 25th. The stock was purchased at an average price of $246.23 per share, with a total value of $499,846.90. Following the acquisition, the director owned 17,483 shares in the company, valued at approximately $4,304,839.09. The trade was a 13.14% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.36% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Winnow Wealth LLC purchased a new stake in shares of Insulet during the third quarter valued at $862,000. Nordea Investment Management AB boosted its holdings in Insulet by 35.0% in the fourth quarter. Nordea Investment Management AB now owns 551,133 shares of the medical instruments supplier’s stock valued at $157,128,000 after purchasing an additional 142,922 shares during the last quarter. Machina Capital S.A.S. purchased a new position in shares of Insulet during the 3rd quarter valued at approximately $2,778,000. Jain Global LLC boosted its stake in shares of Insulet by 148.2% during the 3rd quarter. Jain Global LLC now owns 106,710 shares of the medical instruments supplier’s stock worth $32,945,000 after acquiring an additional 63,719 shares in the last quarter. Finally, ING Groep NV boosted its stake in shares of Insulet by 88.5% during the 3rd quarter. ING Groep NV now owns 17,300 shares of the medical instruments supplier’s stock worth $5,341,000 after acquiring an additional 8,123 shares in the last quarter.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.